BRIEF published on 04/10/2025 at 19:05, 9 months 23 days ago TME Pharma strengthens its liquidity contract with Invest Securities Liquidity Contract Oncology INVEST SECURITIES Financial Markets TME Pharma
PRESS RELEASE published on 04/10/2025 at 19:00, 9 months 23 days ago Inside Information / Other news releases TME Pharma increases resources for liquidity contract with Invest Securities by €5,000 to support cash balance and securities. Details of shares and cash balance provided Liquidity Contract INVEST SECURITIES Clinical-stage Biotechnology Resources TME Pharma
BRIEF published on 02/17/2025 at 08:05, 11 months 14 days ago TME Pharma Outlines 2025 Strategic Roadmap and Initiatives Strategic Partnerships Biotechnology Drug Discovery Cancer Therapy NOX-A12
PRESS RELEASE published on 02/17/2025 at 08:00, 11 months 14 days ago Inside Information / Other news releases TME Pharma CEO Aram Mangasarian outlines key initiatives and milestones for 2025, including strategic partnerships, NOX-A12 clinical development, AI-driven drug discovery, and financial updates Strategic Partnerships Clinical Development CEO Message TME Pharma 2025 Initiatives
BRIEF published on 01/29/2025 at 08:05, 1 year ago TME Pharma and aimed analytics: Innovative partnership for drug discovery through AI Biotechnology Artificial Intelligence Partnership Cancer Drugs
PRESS RELEASE published on 01/29/2025 at 08:00, 1 year ago Inside Information / Other news releases TME Pharma collaborates with aimed analytics for AI-driven drug discovery, strengthening capabilities for strategic transactions. The partnership utilizes AI to accelerate drug development and optimize existing therapies Strategic Partnerships Cancer Treatment TME Pharma AI-driven Drug Discovery Aimed Analytics
BRIEF published on 12/23/2024 at 21:09, 1 year 1 month ago Successful public offering of TME Pharma NV Shareholders Capital Increase Cancer Financial Strategies NOX-A12
BRIEF published on 12/04/2024 at 19:55, 1 year 1 month ago TME Pharma Announces Strategic Update and €2.6 Million Financing Plan Public Offer Corporate Strategy Financing Plan NOX-A12 Development Shareholder Priority
PRESS RELEASE published on 12/04/2024 at 19:50, 1 year 1 month ago Inside Information / Other news releases TME Pharma announces corporate strategy update with upcoming €2.6 million financing aimed at further developing therapies for cancer treatment through public offer open to shareholders. CEO Mangasarian highlights strategic goals and plans Financing Cancer Treatment Public Offer Corporate Strategy TME Pharma
BRIEF published on 11/23/2024 at 10:59, 1 year 2 months ago TME Pharma Presents Findings on NOX-A12 in Glioblastoma Cancer Therapy Glioblastoma NOX-A12 Immune Checkpoint Inhibition Tumor Microenvironment
Published on 02/03/2026 at 15:00, 4 hours 49 minutes ago Vox Royalty Announces Record 2025 Annual and Quarterly Receipts and Exceeds Annual Guidance
Published on 02/03/2026 at 14:29, 5 hours 20 minutes ago Worksport Ltd. Announces Strategic Partnership With Potomac International Partners to Accelerate Federal Government and Commercial Market Adoption of Clean Energy Ecosystem
Published on 02/03/2026 at 13:58, 5 hours 51 minutes ago QNX and Haleytek Join Forces to Deliver Software-Defined Audio for Volvo Cars' EX60 EV SUV
Published on 02/03/2026 at 13:30, 6 hours 19 minutes ago Alset AI's Lyken.AI Secures Cloud Compute Services Purchase Order from Leading Multinational Technology and Telecommunications Company
Published on 02/03/2026 at 13:30, 6 hours 19 minutes ago Lahontan Selects RESPEC and Kappes Cassiday to Update Santa Fe Mineral Resource Estimate and PEA
Published on 02/03/2026 at 19:38, 11 minutes ago EQS-Adhoc: ams-OSRAM AG: ams OSRAM sells non-optical analog/mixed-signal sensor business to Infineon for EUR 570 m in cash, reduces pro-forma leverage ratio to 2.5 and is creating the leader in Digital Photonics
Published on 02/03/2026 at 19:37, 12 minutes ago ams-OSRAM AG: ams OSRAM sells non-optical analog/mixed-signal sensor business to Infineon for EUR 570 m in cash, reduces pro-forma leverage ratio to 2.5 and is creating the leader in Digital Photonics
Published on 02/03/2026 at 19:06, 43 minutes ago Quarterly Activities Report for the period ending 31 December 2025
Published on 02/03/2026 at 18:39, 1 hour 10 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/03/2026 at 18:30, 1 hour 19 minutes ago TECNIMONT (MAIRE) AND BAKER HUGHES TO COLLABORATE ON LNG INITIATIVES GLOBALLY
Published on 02/03/2026 at 08:00, 11 hours 49 minutes ago EURAZEO & PANTHEON ESTABLISH A NEARLY €500 MILLION PRIVATE DEBT CONTINUATION VEHICLE
Published on 02/03/2026 at 08:00, 11 hours 49 minutes ago Neoen launches three new solar farms in France with a total capacity of 230 MWp
Published on 02/02/2026 at 18:23, 1 day 1 hour ago Monthly disclosure of the total number of shares and voting rights - January 2026
Published on 02/02/2026 at 18:00, 1 day 1 hour ago Covivio - Information on total number of voting rights and share capital
